Upadacitinib (Rinvoq®) for ankylosing spondylitis. HTA ID: 21039

Assessment Status Rapid review complete
HTA ID 21039
Drug Upadacitinib
Brand Rinvoq®
Indication  For active ankylosing spondylitis (AS) in adult patients who have responded inadequately to conventional therapy.
Assessment Process
Rapid review commissioned 01/09/2021
Rapid review completed 11/10/2021
Rapid review outcome A full HTA is not recommended. The NCPE recommends that upadacitinib not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations February 2022.